Review



noncontact microarray printer  (SCIENION)


Bioz Verified Symbol SCIENION is a verified supplier
Bioz Manufacturer Symbol SCIENION manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    SCIENION noncontact microarray printer
    <t>Microarray</t> analysis reveals the effects of GFAP mAb treatment on key inflammatory mediators in glaucomatous retina. ( A - C ) The expression of TLR4 and S100A8 was significantly downregulated by 25–50 µg GFAP mAb treatment compared to the vehicle. The marker for microglial activation, CD68, was significantly decreased in the 25 µg GFAP mAb treatment group. ( D - F ) Proteins of the inflammasome pathway, NLRP3, GSDMD and Caspase-1 were significantly downregulated in the 25 µg GFAP mAb treatment group. With the 50 µg dose, these protein expressions showed a similar downward trend, but without statistical significance. ( G ) Expression profiling of inflammation-associated mediators showed that 25 µg GFAP mAb significantly decreased pro-inflammatory factors (TNF-α, IL-1β, IL-8, MMP9, and IFN-γ), and increased the anti-inflammatory cytokine IL-10 compared to the vehicle group. In contrast, the 50 µg dose significantly reduced IFN-γ only. ( H ) Representative images of spots showing IL-1β levels in the subarrays for each group. Image analysis was conducted with Imagene software, using the median intensity from each spot to calculate the mean of the triplicate spots for each marker. For CD68 and TLR4, due to significant heterogeneity in SDs, statistical analysis was performed using Welch’s ANOVA followed by the Tamhane T2 post hoc test. All other data were analyzed using one-way ANOVA with Tukey’s post hoc test. Data are presented as the mean ± SD; n = 4 per group; * p < 0.05, ** p < 0.01, *** p < 0.001; ns = not significant. TLR4 – Toll-Like Receptor 4. S100A8 – S100 Calcium Binding Protein A8. NLRP3 – NLR Family Pyrin Domain Containing 3. GSDMD – Gasdermin D
    Noncontact Microarray Printer, supplied by SCIENION, used in various techniques. Bioz Stars score: 96/100, based on 318 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarray+printers/sciFLEXARRAYER+S3/pmc12175471-139-7-12
    Average 96 stars, based on 318 article reviews
    noncontact microarray printer - by Bioz Stars, 2026-10
    96/100 stars

    Images

    1) Product Images from "Targeting glial fibrillary acidic protein in glaucoma: a monoclonal antibody approach to modulate glial reactivity and neuroinflammation for neuroprotection"

    Article Title: Targeting glial fibrillary acidic protein in glaucoma: a monoclonal antibody approach to modulate glial reactivity and neuroinflammation for neuroprotection

    Journal: Journal of Neuroinflammation

    doi: 10.1186/s12974-025-03482-8

    Microarray analysis reveals the effects of GFAP mAb treatment on key inflammatory mediators in glaucomatous retina. ( A - C ) The expression of TLR4 and S100A8 was significantly downregulated by 25–50 µg GFAP mAb treatment compared to the vehicle. The marker for microglial activation, CD68, was significantly decreased in the 25 µg GFAP mAb treatment group. ( D - F ) Proteins of the inflammasome pathway, NLRP3, GSDMD and Caspase-1 were significantly downregulated in the 25 µg GFAP mAb treatment group. With the 50 µg dose, these protein expressions showed a similar downward trend, but without statistical significance. ( G ) Expression profiling of inflammation-associated mediators showed that 25 µg GFAP mAb significantly decreased pro-inflammatory factors (TNF-α, IL-1β, IL-8, MMP9, and IFN-γ), and increased the anti-inflammatory cytokine IL-10 compared to the vehicle group. In contrast, the 50 µg dose significantly reduced IFN-γ only. ( H ) Representative images of spots showing IL-1β levels in the subarrays for each group. Image analysis was conducted with Imagene software, using the median intensity from each spot to calculate the mean of the triplicate spots for each marker. For CD68 and TLR4, due to significant heterogeneity in SDs, statistical analysis was performed using Welch’s ANOVA followed by the Tamhane T2 post hoc test. All other data were analyzed using one-way ANOVA with Tukey’s post hoc test. Data are presented as the mean ± SD; n = 4 per group; * p < 0.05, ** p < 0.01, *** p < 0.001; ns = not significant. TLR4 – Toll-Like Receptor 4. S100A8 – S100 Calcium Binding Protein A8. NLRP3 – NLR Family Pyrin Domain Containing 3. GSDMD – Gasdermin D
    Figure Legend Snippet: Microarray analysis reveals the effects of GFAP mAb treatment on key inflammatory mediators in glaucomatous retina. ( A - C ) The expression of TLR4 and S100A8 was significantly downregulated by 25–50 µg GFAP mAb treatment compared to the vehicle. The marker for microglial activation, CD68, was significantly decreased in the 25 µg GFAP mAb treatment group. ( D - F ) Proteins of the inflammasome pathway, NLRP3, GSDMD and Caspase-1 were significantly downregulated in the 25 µg GFAP mAb treatment group. With the 50 µg dose, these protein expressions showed a similar downward trend, but without statistical significance. ( G ) Expression profiling of inflammation-associated mediators showed that 25 µg GFAP mAb significantly decreased pro-inflammatory factors (TNF-α, IL-1β, IL-8, MMP9, and IFN-γ), and increased the anti-inflammatory cytokine IL-10 compared to the vehicle group. In contrast, the 50 µg dose significantly reduced IFN-γ only. ( H ) Representative images of spots showing IL-1β levels in the subarrays for each group. Image analysis was conducted with Imagene software, using the median intensity from each spot to calculate the mean of the triplicate spots for each marker. For CD68 and TLR4, due to significant heterogeneity in SDs, statistical analysis was performed using Welch’s ANOVA followed by the Tamhane T2 post hoc test. All other data were analyzed using one-way ANOVA with Tukey’s post hoc test. Data are presented as the mean ± SD; n = 4 per group; * p < 0.05, ** p < 0.01, *** p < 0.001; ns = not significant. TLR4 – Toll-Like Receptor 4. S100A8 – S100 Calcium Binding Protein A8. NLRP3 – NLR Family Pyrin Domain Containing 3. GSDMD – Gasdermin D

    Techniques Used: Microarray, Expressing, Marker, Activation Assay, Software, Binding Assay

    Related Articles

    Automated:

    Article Title: A microfluidics platform for studying ion and solute transport by isolated synaptic vesicles.
    Article Snippet: .. Patterns of droplets (400 pL) were spotted on the coverslips using an automated piezo driven, non-contact dispensing system for ultra-low volumes (sciFLEXARRAYER S3, Scienion GmBH, Berlin, Germany). ..

    Article Title: Rapid classification of live bacteria in blood using antimicrobial peptide microarrays.
    Article Snippet: .. Peptide arraying was performed by printing 6 droplets of 280 to 360 pL each per spot using a sciFLEXARRAYER S3 (Scienion, Berlin, Germany) automated piezo-dispenser. ..

    other:

    Article Title: Spatially resolved, multimodal in vivo Perturb-seq using antibody-based cell hashing
    Article Snippet: Once fabricated, the chips were then filled via piezo-driven non-contact liquid dispensing (sciFLEXARRAYER S3, Scienion AG) using a custom program to fill the wells with a specific barcode layout.

    Article Title: Grating-coupled fluorescent plasmonic (GC-FP) biosensor for point-of-care serological detection of Lyme Disease.
    Article Snippet: Thin films of 5 nm titanium (adhesion layer) and 70 nm gold (plasmonic layer) were deposited using an electron beam evaporator in the University at Albany's College of Nanotechnology, Science & Engineering Innovation Lab. All of the mentioned antigens, HSA, human IgG, and human IgM, were deposited onto the chip's surface using a SciFLEXARRAYER S3 from SCIENION GmbH as described previously (Taubner et al., 2024).

    Control:

    Article Title: Label matters: comparing gold nanoparticles and nanoshells with upconversion nanoparticles for quantitative lateral flow immunoassays
    Article Snippet: .. For dip-stick tests with piezo-driven line deposition (Fig. c), antibodies were dispensed onto the test and control lines on the nitrocellulose membrane using the sciFLEXARRAYER S3 (Scienion, Germany), and the membrane was then attached to a plastic support along with an absorbent and a sample pad. ..

    Membrane:

    Article Title: Label matters: comparing gold nanoparticles and nanoshells with upconversion nanoparticles for quantitative lateral flow immunoassays
    Article Snippet: .. For dip-stick tests with piezo-driven line deposition (Fig. c), antibodies were dispensed onto the test and control lines on the nitrocellulose membrane using the sciFLEXARRAYER S3 (Scienion, Germany), and the membrane was then attached to a plastic support along with an absorbent and a sample pad. ..

    Microarray:

    Article Title: Stage-associated immunoproteomic profiling of serum autoantibody-captured retinal antigens in age-related macular degeneration
    Article Snippet: .. Commercially obtained antigens ( ) were spotted in triplicates onto nitrocellulose-coated slides (Oncyte, Grace Bio Labs, USA) using a non-contact microarray spotter (sciFLEXARRAYER S3, Scienion, Germany). ..

    Single Cell:

    Article Title: Minimally invasive monitoring of clonal evolution through integrated single cell and ctDNA analysis
    Article Snippet: .. This single cell suspension was loaded into a contactless piezoelectric dispenser (sciFLEXARRAYER S3, Scienion) and spotted in open nanowell arrays (SmartChip, TakaraBio) preprinted with unique dual index sequencing primer pairs. .. Libraries were sequenced at UBC Biomedical Research Centre (BRC) in Vancouver, British Columbia on the Illumina NextSeq 550 (mid- or high-output, paired-end 150-bp reads), or at the GSC on Illumina HiSeq2500 (paired-end 125- bp reads) and Illumina HiSeqX (paired-end 150-bp reads).

    Suspension:

    Article Title: Minimally invasive monitoring of clonal evolution through integrated single cell and ctDNA analysis
    Article Snippet: .. This single cell suspension was loaded into a contactless piezoelectric dispenser (sciFLEXARRAYER S3, Scienion) and spotted in open nanowell arrays (SmartChip, TakaraBio) preprinted with unique dual index sequencing primer pairs. .. Libraries were sequenced at UBC Biomedical Research Centre (BRC) in Vancouver, British Columbia on the Illumina NextSeq 550 (mid- or high-output, paired-end 150-bp reads), or at the GSC on Illumina HiSeq2500 (paired-end 125- bp reads) and Illumina HiSeqX (paired-end 150-bp reads).

    Sequencing:

    Article Title: Minimally invasive monitoring of clonal evolution through integrated single cell and ctDNA analysis
    Article Snippet: .. This single cell suspension was loaded into a contactless piezoelectric dispenser (sciFLEXARRAYER S3, Scienion) and spotted in open nanowell arrays (SmartChip, TakaraBio) preprinted with unique dual index sequencing primer pairs. .. Libraries were sequenced at UBC Biomedical Research Centre (BRC) in Vancouver, British Columbia on the Illumina NextSeq 550 (mid- or high-output, paired-end 150-bp reads), or at the GSC on Illumina HiSeq2500 (paired-end 125- bp reads) and Illumina HiSeqX (paired-end 150-bp reads).



    Similar Products

    95
    SCIENION non contact inkjet microarray printer
    The VANC-D4 assay (A) Fabrication of the VANC-D4 assay. SI-ATRP is used to grow POEGMA-co-GMA brushes on glass slides. Following SI-ATRP, VANC-BSA is <t>inkjet</t> printed into the polymer brush to create stable spots and fluorescently labeled anti-VANC antibodies (termed dAb) are printed on trehalose pads to create labile spots. (B) Sequential steps of the VANC-D4 assay. The steps of the VANC-D4 are (i) dispensing a blood sample on the surface, (ii) dissolution of the trehalose pads to release the fluorescently labeled dAb into solution, (iii) diffusion of the labeled dAb in the sample volume, (iv) detection of fluorescence signal from the antibody bound to immobilized VANC-BSA. (C) Representative VANC-D4 assay response in the presence of (i) no drug, (ii) low drug, and (iii) high drug concentration. (D) VANC monitoring across its clinical range using VANC-spiked whole blood diluted 100-fold in running buffer, analyzed in triplicate. The clinical range for the test is 1–45 μg/mL. Intensity values are shown, with error bars that represent the standard error of the means for n = 3 separate runs. The LOD for the presented dose-response curve was calculated to be 0.8 μg/mL.
    Non Contact Inkjet Microarray Printer, supplied by SCIENION, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarray+printers/sciFLEXARRAYER+S12/pmc13380757-243-19-23
    Average 95 stars, based on 1 article reviews
    non contact inkjet microarray printer - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    86
    Digilabs Inc omni grid accent robotic microarray printer
    The VANC-D4 assay (A) Fabrication of the VANC-D4 assay. SI-ATRP is used to grow POEGMA-co-GMA brushes on glass slides. Following SI-ATRP, VANC-BSA is <t>inkjet</t> printed into the polymer brush to create stable spots and fluorescently labeled anti-VANC antibodies (termed dAb) are printed on trehalose pads to create labile spots. (B) Sequential steps of the VANC-D4 assay. The steps of the VANC-D4 are (i) dispensing a blood sample on the surface, (ii) dissolution of the trehalose pads to release the fluorescently labeled dAb into solution, (iii) diffusion of the labeled dAb in the sample volume, (iv) detection of fluorescence signal from the antibody bound to immobilized VANC-BSA. (C) Representative VANC-D4 assay response in the presence of (i) no drug, (ii) low drug, and (iii) high drug concentration. (D) VANC monitoring across its clinical range using VANC-spiked whole blood diluted 100-fold in running buffer, analyzed in triplicate. The clinical range for the test is 1–45 μg/mL. Intensity values are shown, with error bars that represent the standard error of the means for n = 3 separate runs. The LOD for the presented dose-response curve was calculated to be 0.8 μg/mL.
    Omni Grid Accent Robotic Microarray Printer, supplied by Digilabs Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarray+printers/pmc13140502-92-35-41
    Average 86 stars, based on 1 article reviews
    omni grid accent robotic microarray printer - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    86
    Musashi Engineering Inc 350pc microarray printer
    The VANC-D4 assay (A) Fabrication of the VANC-D4 assay. SI-ATRP is used to grow POEGMA-co-GMA brushes on glass slides. Following SI-ATRP, VANC-BSA is <t>inkjet</t> printed into the polymer brush to create stable spots and fluorescently labeled anti-VANC antibodies (termed dAb) are printed on trehalose pads to create labile spots. (B) Sequential steps of the VANC-D4 assay. The steps of the VANC-D4 are (i) dispensing a blood sample on the surface, (ii) dissolution of the trehalose pads to release the fluorescently labeled dAb into solution, (iii) diffusion of the labeled dAb in the sample volume, (iv) detection of fluorescence signal from the antibody bound to immobilized VANC-BSA. (C) Representative VANC-D4 assay response in the presence of (i) no drug, (ii) low drug, and (iii) high drug concentration. (D) VANC monitoring across its clinical range using VANC-spiked whole blood diluted 100-fold in running buffer, analyzed in triplicate. The clinical range for the test is 1–45 μg/mL. Intensity values are shown, with error bars that represent the standard error of the means for n = 3 separate runs. The LOD for the presented dose-response curve was calculated to be 0.8 μg/mL.
    350pc Microarray Printer, supplied by Musashi Engineering Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarray+printers/350pc+image+master+smart/10__1016_slash_j__microc__2026__117169-61-22-21
    Average 86 stars, based on 1 article reviews
    350pc microarray printer - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    95
    SCIENION microarray printer sciflexarrayer s12
    The VANC-D4 assay (A) Fabrication of the VANC-D4 assay. SI-ATRP is used to grow POEGMA-co-GMA brushes on glass slides. Following SI-ATRP, VANC-BSA is <t>inkjet</t> printed into the polymer brush to create stable spots and fluorescently labeled anti-VANC antibodies (termed dAb) are printed on trehalose pads to create labile spots. (B) Sequential steps of the VANC-D4 assay. The steps of the VANC-D4 are (i) dispensing a blood sample on the surface, (ii) dissolution of the trehalose pads to release the fluorescently labeled dAb into solution, (iii) diffusion of the labeled dAb in the sample volume, (iv) detection of fluorescence signal from the antibody bound to immobilized VANC-BSA. (C) Representative VANC-D4 assay response in the presence of (i) no drug, (ii) low drug, and (iii) high drug concentration. (D) VANC monitoring across its clinical range using VANC-spiked whole blood diluted 100-fold in running buffer, analyzed in triplicate. The clinical range for the test is 1–45 μg/mL. Intensity values are shown, with error bars that represent the standard error of the means for n = 3 separate runs. The LOD for the presented dose-response curve was calculated to be 0.8 μg/mL.
    Microarray Printer Sciflexarrayer S12, supplied by SCIENION, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarray+printers/sciFLEXARRAYER+S12/pmc12888686-149-66-70
    Average 95 stars, based on 1 article reviews
    microarray printer sciflexarrayer s12 - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    90
    Arrayjet Limited sprint microarray printer
    Comprehensive <t>microarray</t> polymer profiling (CoMPP) from Arabidopsis thaliana wild type and ARAK1‐OE seedlings grown on 3 mM L‐Ara. Analysis of cell wall composition by carbohydrate profiling is shown. Alcohol‐insoluble residue (AIR) samples were isolated from roots of wild type (WT) and ARAK1‐OE mutants growing for 14 days on 0.5× MS‐agar plates supplemented with 3 mM L‐Ara. Cell wall components were extracted from AIR samples with diaminocyclo‐hexane‐tetra‐acetic acid (CDTA) and NaOH. Blue colors indicate increased intensity of respective antibody binding according to the legend.
    Sprint Microarray Printer, supplied by Arrayjet Limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarray+printers/sprint+microarray+printer/pmc12281597-207-11-15
    Average 90 stars, based on 1 article reviews
    sprint microarray printer - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    96
    SCIENION noncontact microarray printer
    <t>Microarray</t> analysis reveals the effects of GFAP mAb treatment on key inflammatory mediators in glaucomatous retina. ( A - C ) The expression of TLR4 and S100A8 was significantly downregulated by 25–50 µg GFAP mAb treatment compared to the vehicle. The marker for microglial activation, CD68, was significantly decreased in the 25 µg GFAP mAb treatment group. ( D - F ) Proteins of the inflammasome pathway, NLRP3, GSDMD and Caspase-1 were significantly downregulated in the 25 µg GFAP mAb treatment group. With the 50 µg dose, these protein expressions showed a similar downward trend, but without statistical significance. ( G ) Expression profiling of inflammation-associated mediators showed that 25 µg GFAP mAb significantly decreased pro-inflammatory factors (TNF-α, IL-1β, IL-8, MMP9, and IFN-γ), and increased the anti-inflammatory cytokine IL-10 compared to the vehicle group. In contrast, the 50 µg dose significantly reduced IFN-γ only. ( H ) Representative images of spots showing IL-1β levels in the subarrays for each group. Image analysis was conducted with Imagene software, using the median intensity from each spot to calculate the mean of the triplicate spots for each marker. For CD68 and TLR4, due to significant heterogeneity in SDs, statistical analysis was performed using Welch’s ANOVA followed by the Tamhane T2 post hoc test. All other data were analyzed using one-way ANOVA with Tukey’s post hoc test. Data are presented as the mean ± SD; n = 4 per group; * p < 0.05, ** p < 0.01, *** p < 0.001; ns = not significant. TLR4 – Toll-Like Receptor 4. S100A8 – S100 Calcium Binding Protein A8. NLRP3 – NLR Family Pyrin Domain Containing 3. GSDMD – Gasdermin D
    Noncontact Microarray Printer, supplied by SCIENION, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarray+printers/sciFLEXARRAYER+S3/pmc12175471-139-7-12
    Average 96 stars, based on 1 article reviews
    noncontact microarray printer - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    Image Search Results


    The VANC-D4 assay (A) Fabrication of the VANC-D4 assay. SI-ATRP is used to grow POEGMA-co-GMA brushes on glass slides. Following SI-ATRP, VANC-BSA is inkjet printed into the polymer brush to create stable spots and fluorescently labeled anti-VANC antibodies (termed dAb) are printed on trehalose pads to create labile spots. (B) Sequential steps of the VANC-D4 assay. The steps of the VANC-D4 are (i) dispensing a blood sample on the surface, (ii) dissolution of the trehalose pads to release the fluorescently labeled dAb into solution, (iii) diffusion of the labeled dAb in the sample volume, (iv) detection of fluorescence signal from the antibody bound to immobilized VANC-BSA. (C) Representative VANC-D4 assay response in the presence of (i) no drug, (ii) low drug, and (iii) high drug concentration. (D) VANC monitoring across its clinical range using VANC-spiked whole blood diluted 100-fold in running buffer, analyzed in triplicate. The clinical range for the test is 1–45 μg/mL. Intensity values are shown, with error bars that represent the standard error of the means for n = 3 separate runs. The LOD for the presented dose-response curve was calculated to be 0.8 μg/mL.

    Journal: iScience

    Article Title: A rapid point-of-care test for vancomycin monitoring at the clinical bedside

    doi: 10.1016/j.isci.2026.116064

    Figure Lengend Snippet: The VANC-D4 assay (A) Fabrication of the VANC-D4 assay. SI-ATRP is used to grow POEGMA-co-GMA brushes on glass slides. Following SI-ATRP, VANC-BSA is inkjet printed into the polymer brush to create stable spots and fluorescently labeled anti-VANC antibodies (termed dAb) are printed on trehalose pads to create labile spots. (B) Sequential steps of the VANC-D4 assay. The steps of the VANC-D4 are (i) dispensing a blood sample on the surface, (ii) dissolution of the trehalose pads to release the fluorescently labeled dAb into solution, (iii) diffusion of the labeled dAb in the sample volume, (iv) detection of fluorescence signal from the antibody bound to immobilized VANC-BSA. (C) Representative VANC-D4 assay response in the presence of (i) no drug, (ii) low drug, and (iii) high drug concentration. (D) VANC monitoring across its clinical range using VANC-spiked whole blood diluted 100-fold in running buffer, analyzed in triplicate. The clinical range for the test is 1–45 μg/mL. Intensity values are shown, with error bars that represent the standard error of the means for n = 3 separate runs. The LOD for the presented dose-response curve was calculated to be 0.8 μg/mL.

    Article Snippet: Following polymerization, D4 assays were fabricated using non-contact inkjet printing methods as described elsewhere., VANC-BSA was printed using a non-contact inkjet microarray printer (Scienion, sciFLEXARRAYER Type S12).

    Techniques: Polymer, Labeling, Dissolution, Diffusion-based Assay, Fluorescence, Concentration Assay

    Comprehensive microarray polymer profiling (CoMPP) from Arabidopsis thaliana wild type and ARAK1‐OE seedlings grown on 3 mM L‐Ara. Analysis of cell wall composition by carbohydrate profiling is shown. Alcohol‐insoluble residue (AIR) samples were isolated from roots of wild type (WT) and ARAK1‐OE mutants growing for 14 days on 0.5× MS‐agar plates supplemented with 3 mM L‐Ara. Cell wall components were extracted from AIR samples with diaminocyclo‐hexane‐tetra‐acetic acid (CDTA) and NaOH. Blue colors indicate increased intensity of respective antibody binding according to the legend.

    Journal: Plant Direct

    Article Title: Arabinokinase Limits the Flux of Arabinose Into Nucleotide Sugars to Prevent Toxicity

    doi: 10.1002/pld3.70094

    Figure Lengend Snippet: Comprehensive microarray polymer profiling (CoMPP) from Arabidopsis thaliana wild type and ARAK1‐OE seedlings grown on 3 mM L‐Ara. Analysis of cell wall composition by carbohydrate profiling is shown. Alcohol‐insoluble residue (AIR) samples were isolated from roots of wild type (WT) and ARAK1‐OE mutants growing for 14 days on 0.5× MS‐agar plates supplemented with 3 mM L‐Ara. Cell wall components were extracted from AIR samples with diaminocyclo‐hexane‐tetra‐acetic acid (CDTA) and NaOH. Blue colors indicate increased intensity of respective antibody binding according to the legend.

    Article Snippet: Arrays were printed as distinct dots onto nitrocellulose membranes with an ArrayJet Sprint microarray printer (ArrayJet, Roslin, UK) and probed with ~40 cell wall probes, including antibodies and carbohydrate binding modules (Table ).

    Techniques: Microarray, Polymer, Residue, Isolation, Binding Assay

    Microarray analysis reveals the effects of GFAP mAb treatment on key inflammatory mediators in glaucomatous retina. ( A - C ) The expression of TLR4 and S100A8 was significantly downregulated by 25–50 µg GFAP mAb treatment compared to the vehicle. The marker for microglial activation, CD68, was significantly decreased in the 25 µg GFAP mAb treatment group. ( D - F ) Proteins of the inflammasome pathway, NLRP3, GSDMD and Caspase-1 were significantly downregulated in the 25 µg GFAP mAb treatment group. With the 50 µg dose, these protein expressions showed a similar downward trend, but without statistical significance. ( G ) Expression profiling of inflammation-associated mediators showed that 25 µg GFAP mAb significantly decreased pro-inflammatory factors (TNF-α, IL-1β, IL-8, MMP9, and IFN-γ), and increased the anti-inflammatory cytokine IL-10 compared to the vehicle group. In contrast, the 50 µg dose significantly reduced IFN-γ only. ( H ) Representative images of spots showing IL-1β levels in the subarrays for each group. Image analysis was conducted with Imagene software, using the median intensity from each spot to calculate the mean of the triplicate spots for each marker. For CD68 and TLR4, due to significant heterogeneity in SDs, statistical analysis was performed using Welch’s ANOVA followed by the Tamhane T2 post hoc test. All other data were analyzed using one-way ANOVA with Tukey’s post hoc test. Data are presented as the mean ± SD; n = 4 per group; * p < 0.05, ** p < 0.01, *** p < 0.001; ns = not significant. TLR4 – Toll-Like Receptor 4. S100A8 – S100 Calcium Binding Protein A8. NLRP3 – NLR Family Pyrin Domain Containing 3. GSDMD – Gasdermin D

    Journal: Journal of Neuroinflammation

    Article Title: Targeting glial fibrillary acidic protein in glaucoma: a monoclonal antibody approach to modulate glial reactivity and neuroinflammation for neuroprotection

    doi: 10.1186/s12974-025-03482-8

    Figure Lengend Snippet: Microarray analysis reveals the effects of GFAP mAb treatment on key inflammatory mediators in glaucomatous retina. ( A - C ) The expression of TLR4 and S100A8 was significantly downregulated by 25–50 µg GFAP mAb treatment compared to the vehicle. The marker for microglial activation, CD68, was significantly decreased in the 25 µg GFAP mAb treatment group. ( D - F ) Proteins of the inflammasome pathway, NLRP3, GSDMD and Caspase-1 were significantly downregulated in the 25 µg GFAP mAb treatment group. With the 50 µg dose, these protein expressions showed a similar downward trend, but without statistical significance. ( G ) Expression profiling of inflammation-associated mediators showed that 25 µg GFAP mAb significantly decreased pro-inflammatory factors (TNF-α, IL-1β, IL-8, MMP9, and IFN-γ), and increased the anti-inflammatory cytokine IL-10 compared to the vehicle group. In contrast, the 50 µg dose significantly reduced IFN-γ only. ( H ) Representative images of spots showing IL-1β levels in the subarrays for each group. Image analysis was conducted with Imagene software, using the median intensity from each spot to calculate the mean of the triplicate spots for each marker. For CD68 and TLR4, due to significant heterogeneity in SDs, statistical analysis was performed using Welch’s ANOVA followed by the Tamhane T2 post hoc test. All other data were analyzed using one-way ANOVA with Tukey’s post hoc test. Data are presented as the mean ± SD; n = 4 per group; * p < 0.05, ** p < 0.01, *** p < 0.001; ns = not significant. TLR4 – Toll-Like Receptor 4. S100A8 – S100 Calcium Binding Protein A8. NLRP3 – NLR Family Pyrin Domain Containing 3. GSDMD – Gasdermin D

    Article Snippet: Briefly, the microarray was prepared using a noncontact microarray printer (SciFLEXARRAYER S3; Scienion, Berlin, Germany).

    Techniques: Microarray, Expressing, Marker, Activation Assay, Software, Binding Assay